Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A

Manco-Johnson, 2003, Advances in care of children with hemophilia, Semin Thromb Hemost, 29, 585, 10.1055/s-2004-815626 Mannucci, 2001, The hemophilias—from royal genes to gene therapy, N Engl J Med, 344, 1773, 10.1056/NEJM200106073442307 Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 357, 535, 10.1056/NEJMoa067659 Nilsson, 1992, Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B, J Intern Med, 232, 25, 10.1111/j.1365-2796.1992.tb00546.x National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding), 2007. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57{00AMP00}contentid=1007. Accessed 30 January 2015. Hacker, 2001, Barriers to compliance with prophylaxis therapy in haemophilia, Haemophilia, 7, 392, 10.1111/j.1365-2516.2001.00534.x Zappa, 2012, Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey, Haemophilia, 18, e140, 10.1111/j.1365-2516.2012.02770.x Fogarty, 2011, Biological rationale for new drugs in the bleeding disorders pipeline, Hematology Am Soc Hematol Educ Program, 2011, 397, 10.1182/asheducation-2011.1.397 Bjorkman, 2012, Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight, Blood, 119, 612, 10.1182/blood-2011-07-360594 Peters, 2013, Biochemical and functional characterization of a recombinant monomeric factor VIII Fc fusion protein, J Thromb Haemost, 11, 132, 10.1111/jth.12076 Rath, 2013, Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics, Crit Rev Biotechnol Mahlangu, 2013, Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A, Blood, 123, 317, 10.1182/blood-2013-10-529974 Gouw, 2012, F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis, Blood, 119, 2922, 10.1182/blood-2011-09-379453 Margaglione, 2008, The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype, Haematologica, 93, 722, 10.3324/haematol.12427 European Medicines Agency. Guideline on clinical investigation of recombinant and human plasma-derived factor VIII products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109692.pdf. Accessed 5 June 2014. United States Food and Drug Administration. Guidance for industry: assay development for immunogenicity testing of therapeutic proteins. December 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM192750.pdf. Accessed 5 June 2014. Baxter Healthcare Corporation. Advate [antihemophilic factor (recombinant), plasma/albumin-free method] (package insert). July 2012. http://www.advate.com/assets/pdf/advate_iri_pi.pdf. Accessed 17 July 2014. Kulkarni, 2013, Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics, Haemophilia, 19, 698, 10.1111/hae.12165 Powell, 2012, Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients, Blood, 119, 3031, 10.1182/blood-2011-09-382846 Gringeri, 2011, A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study), J Thromb Haemost, 9, 700, 10.1111/j.1538-7836.2011.04214.x Khawaji, 2010, Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis, Haemophilia, 16, 495, 10.1111/j.1365-2516.2009.02186.x Ross, 2009, Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis, Pediatrics, 124, 1267, 10.1542/peds.2009-0072 DiMichele, 2002, Inhibitors: resolving diagnostic and therapeutic dilemmas, Haemophilia, 8, 280, 10.1046/j.1365-2516.2002.00626.x Gringeri, 2004, Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII, Br J Haematol, 126, 398, 10.1111/j.1365-2141.2004.05058.x Xi, 2013, Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression, J Thromb Haemost, 11, 1655, 10.1111/jth.12335 Valentino, 2014, The first recombinant FVIII produced in human cells—an update on its clinical development programme, Haemophilia, 20, 1, 10.1111/hae.12322 Batlle, 1996, Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects, Ann Hematol, 72, 321, 10.1007/s002770050179 Klintman, 2013, Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A, Haemophilia, 19, 106, 10.1111/j.1365-2516.2012.02903.x Krudysz-Amblo, 2009, Quantitation of anti-factor VIII antibodies in human plasma, Blood, 113, 2587, 10.1182/blood-2008-08-174987 Dazzi, 1996, High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII, Br J Haematol, 93, 688, 10.1046/j.1365-2141.1996.d01-1705.x Klintman, 2013, Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy, Br J Haematol, 163, 385, 10.1111/bjh.12540 van Dijk, 2005, Factor VIII half-life and clinical phenotype of severe hemophilia A, Haematologica, 90, 494 Bjorkman, 2009, Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A, Eur J Clin Pharmacol, 65, 989, 10.1007/s00228-009-0676-x Bjorkman, 2010, Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring, J Thromb Haemost, 8, 730, 10.1111/j.1538-7836.2010.03757.x Terraube, 2010, Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance, Haemophilia, 16, 3, 10.1111/j.1365-2516.2009.02005.x Gallinaro, 2008, A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor, Blood, 111, 3540, 10.1182/blood-2007-11-122945 Kumar, 2013, Effect of unstructured polypeptide insertions on the recombinant expression of human factor VIII, J Thromb Haemost, 11, 711. Mei, 2010, Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment, Blood, 116, 270, 10.1182/blood-2009-11-254755 Tiede, 2013, Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-man trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A, J Thromb Haemost, 11, 670, 10.1111/jth.12161 Fogarty, 2014, Analysis of baseline characteristics and 5-day dosing interval with rFVIIIFc in the phase 3 A-LONG study, Am J Hematol, 89, E35. DiMichele, 2012, Clinical trial design in haemophilia, Haemophilia, 18, 18, 10.1111/j.1365-2516.2012.02824.x McIntosh, 2013, Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant, Blood, 121, 3335, 10.1182/blood-2012-10-462200 Nathwani, 2011, Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, 365, 2357, 10.1056/NEJMoa1108046